Details of the Drug

General Information of Drug (ID: DMLB0EZ)

Drug Name
Tamoxifen
Synonyms
tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno;Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [1]
Inflammatory breast cancer 2C62 Approved [2]
Invasive ductal breast carcinoma N.A. Approved [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 371.5
Logarithm of the Partition Coefficient (xlogp) 7.1
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 40 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 5 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The clearance of drug is 189 mL/min in postmenopausal women [5]
Elimination
Animal studies have shown 75% of radiolabelled tamoxifen recovered in the feces, with negligible collection from urine [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 - 7 days [3]
Metabolism
The drug is metabolized via the hydroxylated to -hydroxytamoxifen [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.18283 micromolar/kg/day [8]
Vd
The volume of distribution (Vd) of drug is 50-60 L/kg [9]
Water Solubility
The ability of drug to dissolve in water is measured as 0.5 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Thromboembolic event rs6025 F5 OTDMZ3LT [10]
Chemical Identifiers
Formula
C26H29NO
IUPAC Name
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
Canonical SMILES
CC/C(=C(\\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
InChI
InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
InChIKey
NKANXQFJJICGDU-QPLCGJKRSA-N
Cross-matching ID
PubChem CID
2733526
ChEBI ID
CHEBI:41774
CAS Number
10540-29-1
DrugBank ID
DB00675
TTD ID
D07KSG
VARIDT ID
DR00193
INTEDE ID
DR1529
ACDINA ID
D00650
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Antagonist [11]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 7 (ABCC10) DTPS120 MRP7_HUMAN Substrate [12]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [13]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [14]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [15]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [16]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [17]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [18]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [19]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [20]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [21]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [16]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [22]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [23]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [24]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [25]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [26]
Sulfotransferase 2A1 (SULT2A1)
Main DME 		DE0P6LK ST2A1_HUMAN Substrate []
Sulfotransferase 1A1 (SULT1A1) DEYWLRK ST1A1_HUMAN Substrate [27]
UDP-glucuronosyltransferase 1A10 (UGT1A10) DEL5N6Y UD110_HUMAN Substrate [28]
Thiopurine methyltransferase (TPMT) DEFQ8VO TPMT_HUMAN Substrate [29]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Coagulation factor V (F5) OTDMZ3LT FA5_HUMAN Drug Response [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
P-glycoprotein 1 (ABCB1) DTP P-GP 7.23E-01 -8.20E-02 -3.22E-01
Multidrug resistance-associated protein 7 (ABCC10) DTP MRP7 6.29E-01 6.44E-02 9.67E-02
Breast cancer resistance protein (ABCG2) DTP BCRP 9.93E-01 -1.09E-01 -5.77E-01
Sulfotransferase 1A1 (SULT1A1) DME SULT1A1 6.22E-02 1.64E-01 5.58E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 7.69E-01 1.91E-02 5.45E-02
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 7.75E-01 -1.76E-01 -6.23E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 3.97E-02 -1.72E-01 -9.29E-01
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 7.56E-01 -6.70E-02 -3.47E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 9.96E-01 -7.53E-02 -5.68E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 5.82E-01 -6.00E-02 -2.69E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 3.44E-01 -1.85E-01 -5.25E-01
Thiopurine methyltransferase (TPMT) DME TPMT 8.48E-01 -1.76E-01 -5.49E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.95E-01 -7.47E-02 -2.45E-01
Cytochrome P450 1A1 (CYP1A1) DME CYP1A1 5.01E-01 -1.01E-02 -6.05E-02
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 9.09E-01 -9.26E-02 -3.68E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.85E-01 2.24E-02 7.33E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tamoxifen
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Eribulin. Breast cancer [2C60-2C6Y] [30]
Talazoparib DM1KS78 Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [31]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Lapatinib. Breast cancer [2C60-2C6Y] [30]
Tucatinib DMBESUA Moderate Decreased metabolism of Tamoxifen caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
Alpelisib DMEXMYK Moderate Increased metabolism of Tamoxifen caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [33]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Bosutinib. Breast cancer [2C60-2C6Y] [34]
⏷ Show the Full List of 6 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Tamoxifen (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Tamoxifen and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [35]
Nateglinide DMLK2QH Moderate Decreased metabolism of Tamoxifen caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [36]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Ivosidenib. Acute myeloid leukaemia [2A60] [37]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Midostaurin. Acute myeloid leukaemia [2A60] [30]
Idarubicin DMM0XGL Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [38]
Daunorubicin DMQUSBT Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Daunorubicin. Acute myeloid leukaemia [2A60] [38]
Arn-509 DMT81LZ Moderate Increased metabolism of Tamoxifen caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [39]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Gilteritinib. Acute myeloid leukaemia [2A60] [40]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Oliceridine. Acute pain [MG31] [30]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Rivastigmine. Alzheimer disease [8A20] [30]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Donepezil. Alzheimer disease [8A20] [30]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Tamoxifen and Metronidazole. Amoebiasis [1A36] [35]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Ivabradine. Angina pectoris [BA40] [34]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Bepridil. Angina pectoris [BA40] [30]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Dronedarone. Angina pectoris [BA40] [30]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Tamoxifen and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [41]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Tamoxifen caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [39]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Posaconazole. Aspergillosis [1F20] [30]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Levalbuterol. Asthma [CA23] [42]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Terbutaline. Asthma [CA23] [43]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Pirbuterol. Asthma [CA23] [43]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Salbutamol. Asthma [CA23] [42]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Formoterol. Asthma [CA23] [43]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [34]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Desipramine. Attention deficit hyperactivity disorder [6A05] [30]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Ofloxacin. Bacterial infection [1A00-1C4Z] [44]
Dalfopristin DM4LTKV Major Decreased metabolism of Tamoxifen caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [45]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Clarithromycin. Bacterial infection [1A00-1C4Z] [30]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Tamoxifen and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [30]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Tamoxifen and Sparfloxacin. Bacterial infection [1A00-1C4Z] [44]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Gemifloxacin. Bacterial infection [1A00-1C4Z] [44]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Norfloxacin. Bacterial infection [1A00-1C4Z] [44]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Levofloxacin. Bacterial infection [1A00-1C4Z] [44]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Lomefloxacin. Bacterial infection [1A00-1C4Z] [30]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Telithromycin. Bacterial infection [1A00-1C4Z] [30]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Tamoxifen and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [46]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [47]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Olodaterol. Chronic obstructive pulmonary disease [CA22] [43]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Vilanterol. Chronic obstructive pulmonary disease [CA22] [42]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Salmeterol. Chronic obstructive pulmonary disease [CA22] [43]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Indacaterol. Chronic obstructive pulmonary disease [CA22] [43]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Arformoterol. Chronic obstructive pulmonary disease [CA22] [43]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Tamoxifen caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [39]
Fidaxomicin DMFP6MV Minor Decreased clearance of Tamoxifen due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [35]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Isoproterenol. Conduction disorder [BC63] [42]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Halothane. Corneal disease [9A76-9A78] [30]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Propofol. Corneal disease [9A76-9A78] [48]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Probucol. Coronary atherosclerosis [BA80] [30]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Tamoxifen and Mifepristone. Cushing syndrome [5A70] [30]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Tamoxifen and Pasireotide. Cushing syndrome [5A70] [30]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Osilodrostat. Cushing syndrome [5A70] [34]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Tamoxifen caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [49]
MK-8228 DMOB58Q Moderate Decreased metabolism of Tamoxifen caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [50]
Sertraline DM0FB1J Major Decreased metabolism of Tamoxifen caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Trimipramine. Depression [6A70-6A7Z] [30]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Tamoxifen caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [52]
Paroxetine DM5PVQE Major Decreased metabolism of Tamoxifen caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Clomipramine. Depression [6A70-6A7Z] [30]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Doxepin. Depression [6A70-6A7Z] [30]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Maprotiline. Depression [6A70-6A7Z] [30]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [30]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Tamoxifen and Deutetrabenazine. Dystonic disorder [8A02] [53]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Ingrezza. Dystonic disorder [8A02] [54]
Primidone DM0WX6I Moderate Increased metabolism of Tamoxifen caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Felbamate DM1V5ZS Moderate Increased metabolism of Tamoxifen caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Cenobamate DM8KLU9 Moderate Increased metabolism of Tamoxifen caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Tamoxifen caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Phenobarbital DMXZOCG Moderate Increased metabolism of Tamoxifen caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Tamoxifen and Cannabidiol. Epileptic encephalopathy [8A62] [34]
Diphenhydramine DMKQTBA Major Decreased metabolism of Tamoxifen caused by Diphenhydramine mediated inhibition of CYP450 enzyme. Episodic vestibular syndrome [AB31] [51]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Solifenacin. Functional bladder disorder [GC50] [30]
Mirabegron DMS1GYT Major Decreased metabolism of Tamoxifen caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [51]
Itraconazole DMCR1MV Moderate Decreased metabolism of Tamoxifen caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [55]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Pentamidine. Fungal infection [1F29-1F2F] [30]
Terbinafine DMI6HUW Major Decreased metabolism of Tamoxifen caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [51]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Ketoconazole. Fungal infection [1F29-1F2F] [30]
Ripretinib DM958QB Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [35]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Sunitinib. Gastrointestinal stromal tumour [2B5B] [30]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Tamoxifen caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [39]
Rifampin DMA8J1G Moderate Increased metabolism of Tamoxifen caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [39]
Rifapentine DMCHV4I Moderate Increased metabolism of Tamoxifen caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [39]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Tamoxifen and Brentuximab vedotin. Hodgkin lymphoma [2B30] [56]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [57]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Tamoxifen caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [58]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Tamoxifen and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [59]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [30]
Darunavir DMN3GCH Moderate Decreased metabolism of Tamoxifen caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [60]
Maraviroc DMTL94F Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [61]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Tamoxifen caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [35]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Tamoxifen and Mipomersen. Hyper-lipoproteinaemia [5C80] [62]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Tamoxifen and Teriflunomide. Hyper-lipoproteinaemia [5C80] [30]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Tamoxifen and BMS-201038. Hyper-lipoproteinaemia [5C80] [63]
Cinacalcet DMCX0K3 Major Decreased metabolism of Tamoxifen caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [51]
Conivaptan DM1V329 Moderate Decreased metabolism of Tamoxifen caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [64]
Tolvaptan DMIWFRL Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [65]
Givosiran DM5PFIJ Major Decreased metabolism of Tamoxifen caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [51]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Tamoxifen caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [66]
Amobarbital DM0GQ8N Moderate Increased metabolism of Tamoxifen caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [39]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Polyethylene glycol. Irritable bowel syndrome [DD91] [34]
Naloxegol DML0B41 Minor Decreased clearance of Tamoxifen due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [67]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Tamoxifen caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [34]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Tamoxifen and Crizotinib. Lung cancer [2C25] [68]
Brigatinib DM7W94S Moderate Increased metabolism of Tamoxifen caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [69]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Tamoxifen and Ceritinib. Lung cancer [2C25] [30]
PF-06463922 DMKM7EW Moderate Increased metabolism of Tamoxifen caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [39]
Dacomitinib DMOH8VY Major Decreased metabolism of Tamoxifen caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [51]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Tamoxifen and Osimertinib. Lung cancer [2C25] [70]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Tamoxifen and Selpercatinib. Lung cancer [2C25] [34]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Tamoxifen and Lumefantrine. Malaria [1F40-1F45] [35]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Tamoxifen and Hydroxychloroquine. Malaria [1F40-1F45] [71]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Primaquine. Malaria [1F40-1F45] [30]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [34]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Tamoxifen and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [72]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Tamoxifen and Idelalisib. Mature B-cell leukaemia [2A82] [73]
GDC-0199 DMH0QKA Major Decreased clearance of Tamoxifen due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [35]
IPI-145 DMWA24P Moderate Decreased metabolism of Tamoxifen caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [74]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Arsenic trioxide. Mature B-cell lymphoma [2A85] [75]
Arry-162 DM1P6FR Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Arry-162. Melanoma [2C30] [35]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Vemurafenib. Melanoma [2C30] [30]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and LGX818. Melanoma [2C30] [76]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Tamoxifen caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [39]
Ubrogepant DM749I3 Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Ubrogepant. Migraine [8A80] [77]
Exjade DMHPRWG Moderate Decreased metabolism of Tamoxifen caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [78]
Carfilzomib DM48K0X Major Additive thrombogenic effects by the combination of Tamoxifen and Carfilzomib. Multiple myeloma [2A83] [35]
Panobinostat DM58WKG Major Decreased metabolism of Tamoxifen caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [51]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Siponimod. Multiple sclerosis [8A40] [35]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Fingolimod. Multiple sclerosis [8A40] [30]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Ozanimod. Multiple sclerosis [8A40] [79]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Romidepsin. Mycosis fungoides [2B01] [30]
Fedratinib DM4ZBK6 Major Decreased metabolism of Tamoxifen caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [51]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Tamoxifen and Nilotinib. Myeloproliferative neoplasm [2A20] [30]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Dasatinib. Myeloproliferative neoplasm [2A20] [80]
Prasugrel DM7MT6E Minor Decreased metabolism of Tamoxifen caused by Prasugrel mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [34]
Modafinil DMYILBE Moderate Increased metabolism of Tamoxifen caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [39]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Promethazine. Nausea/vomiting [MD90] [30]
Rolapitant DM8XP26 Major Decreased metabolism of Tamoxifen caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [51]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Granisetron. Nausea/vomiting [MD90] [30]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Tamoxifen and Dolasetron. Nausea/vomiting [MD90] [30]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Ondansetron. Nausea/vomiting [MD90] [30]
Bupropion DM5PCS7 Major Decreased metabolism of Tamoxifen caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [51]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Entrectinib. Non-small cell lung cancer [2C25] [35]
Lorcaserin DMG6OYJ Major Decreased metabolism of Tamoxifen caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [51]
Dexfenfluramine DMJ7YDS Major Decreased metabolism of Tamoxifen caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [51]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Levomethadyl Acetate. Opioid use disorder [6C43] [34]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Lofexidine. Opioid use disorder [6C43] [30]
Olaparib DM8QB1D Moderate Increased metabolism of Tamoxifen caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [35]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Rucaparib. Ovarian cancer [2C73] [30]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Buprenorphine. Pain [MG30-MG3Z] [30]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Triclabendazole. Parasitic worm infestation [1F90] [30]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Pimavanserin. Parkinsonism [8A00] [81]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Apomorphine. Parkinsonism [8A00] [30]
Abametapir DM2RX0I Moderate Decreased metabolism of Tamoxifen caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [82]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Famotidine. Peptic ulcer [DA61] [35]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Tamoxifen and Macimorelin. Pituitary gland disorder [5A60-5A61] [83]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Lefamulin. Pneumonia [CA40] [84]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Tamoxifen caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [85]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Ritodrine. Preterm labour/delivery [JB00] [43]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Degarelix. Prostate cancer [2C82] [34]
ABIRATERONE DM8V75C Major Decreased metabolism of Tamoxifen caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [51]
Enzalutamide DMGL19D Moderate Increased metabolism of Tamoxifen caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [39]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Relugolix. Prostate cancer [2C82] [34]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Bicalutamide. Prostate cancer [2C82] [34]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Levomepromazine. Psychotic disorder [6A20-6A25] [30]
Riociguat DMXBLMP Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [35]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Tamoxifen and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [86]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Gatifloxacin. Respiratory infection [CA07-CA4Z] [87]
Dexamethasone DMMWZET Moderate Increased metabolism of Tamoxifen caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [39]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Quetiapine. Schizophrenia [6A20] [30]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Tamoxifen and Mesoridazine. Schizophrenia [6A20] [30]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Tamoxifen and Thioridazine. Schizophrenia [6A20] [30]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Tamoxifen and Iloperidone. Schizophrenia [6A20] [30]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Paliperidone. Schizophrenia [6A20] [30]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Perphenazine. Schizophrenia [6A20] [30]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Trifluoperazine. Schizophrenia [6A20] [30]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Tamoxifen and Amisulpride. Schizophrenia [6A20] [88]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Asenapine. Schizophrenia [6A20] [30]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Tamoxifen and Pimozide. Schizophrenia [6A20] [34]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Vardenafil. Sexual dysfunction [HA00-HA01] [30]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Tamoxifen caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [34]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Tamoxifen and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [34]
Armodafinil DMGB035 Moderate Increased metabolism of Tamoxifen caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [39]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Tamoxifen and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [30]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [34]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [30]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Tamoxifen and Naltrexone. Substance abuse [6C40] [89]
Fostamatinib DM6AUHV Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [90]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [91]
Apixaban DM89JLN Moderate Decreased metabolism of Tamoxifen caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [34]
Clopidogrel DMOL54H Minor Decreased metabolism of Tamoxifen caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [92]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Lenvatinib. Thyroid cancer [2D10] [30]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Cabozantinib. Thyroid cancer [2D10] [34]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Tamoxifen and Papaverine. Tonus and reflex abnormality [MB47] [93]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Tizanidine. Tonus and reflex abnormality [MB47] [30]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Tamoxifen and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [86]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Tacrolimus. Transplant rejection [NE84] [30]
Elagolix DMB2C0E Moderate Increased metabolism of Tamoxifen caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [39]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [94]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Procainamide. Ventricular tachyarrhythmia [BC71] [30]
Propafenone DMPIBJK Major Decreased metabolism of Tamoxifen caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [51]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Flecainide. Ventricular tachyarrhythmia [BC71] [30]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Amiodarone. Ventricular tachyarrhythmia [BC71] [30]
⏷ Show the Full List of 201 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Anethole E00440 637563 Flavoring agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carboxymethylcellulose sodium E00621 Not Available Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium E00625 Not Available Disintegrant
Ethanol E00023 702 Antimicrobial preservative; Penetration agent; Solvent
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
Sorbitan tristearate E00516 17800859 Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Tamoxifen 10 mg tablet 10 mg Oral Tablet Oral
Tamoxifen 20 mg tablet 20 mg Oral Tablet Oral
Tamoxifen Citrate eq 10mg base tablet eq 10mg base Tablet Oral
Tamoxifen Citrate eq 20mg base/10ml solution eq 20mg base/10ml Solution Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1016).
2 Tamoxifen FDA Label
3 FDA Approved Drug Products: Tamoxifen Oral Tablets
4 BDDCS applied to over 900 drugs
5 Lien EA, Anker G, Lonning PE, Solheim E, Ueland PM: Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 1990 Sep 15;50(18):5851-7.
6 Fromson JM, Pearson S, Bramah S: The metabolism of tamoxifen (I.C.I. 46,474). I. In laboratory animals. Xenobiotica. 1973 Nov;3(11):693-709. doi: 10.3109/00498257309151594.
7 Brocks DR: Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 1999 May-Aug;2(2):39-46.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM: Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 1989 Apr 15;49(8):2175-83.
10 Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst. 2010 Jul 7;102(13):942-9. doi: 10.1093/jnci/djq211. Epub 2010 Jun 16.
11 Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86.
12 Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
13 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
14 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
17 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
18 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
19 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
20 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
21 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
22 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
23 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
24 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
25 Drug Interactions Flockhart Table
26 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
27 Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 2010 Jan;38(1):200-7.
28 Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
29 Polymorphism of estrogen metabolism genes and cataract. Med Hypotheses. 2004;63(3):494-7.
30 Canadian Pharmacists Association.
31 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
32 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
33 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
34 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
35 Cerner Multum, Inc. "Australian Product Information.".
36 Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
37 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
38 Multum Information Services, Inc. Expert Review Panel.
39 Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
40 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
41 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
42 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
43 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
44 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
45 Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
46 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
47 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
48 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
49 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
50 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
51 Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
52 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
53 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
54 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
55 Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
56 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
57 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
58 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
59 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
60 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
61 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
62 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
63 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
64 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
65 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
66 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
67 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
68 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
69 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
70 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
71 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
72 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
73 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
74 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
75 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
76 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
77 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
78 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
79 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
80 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
81 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
82 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
83 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
84 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
85 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
86 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
87 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
88 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
89 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
90 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
91 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
92 Product Information. Plavix (clopidogrel). Bristol-Myers Squibb, Princeton, NJ.
93 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
94 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]